Background
Chronic obstructive pulmonary disease (COPD) remains one of the leading causes of morbidity and mortality worldwide, affecting hundreds of millions of individuals across diverse healthcare systems. Among the most consequential events in the natural history of COPD are acute exacerbations (AE-COPD), which accelerate disease progression, impair quality of life, and substantially increase healthcare utilization. Beyond their well-recognized pulmonary impact, acute exacerbations of COPD have increasingly been recognized as systemic inflammatory events with ramifications extending far beyond the lungs. In particular, the cardiovascular consequences of AE-COPD have drawn growing attention from clinicians and researchers alike, as patients experiencing exacerbations face a markedly elevated risk of myocardial infarction, stroke, heart failure, and death in the months following the acute event.
The pathophysiological mechanisms linking AE-COPD to cardiovascular events are multifactorial, involving hypoxemia, sympathetic activation, endothelial dysfunction, prothrombotic states, and the systemic spillover of pulmonary inflammation. However, not all acute exacerbations appear to carry the same cardiovascular risk profile. One emerging area of scientific inquiry concerns the role of blood eosinophil count as a marker that may distinguish between distinct inflammatory phenotypes of COPD exacerbation. Eosinophilic inflammation has long been recognized as a driver of airway disease in a subset of COPD patients, and elevated blood eosinophil levels have been associated with better responses to inhaled corticosteroids and reduced rates of exacerbation in some contexts. Whether the eosinophilic phenotype also confers differential cardiovascular risk during acute exacerbations, however, has remained an important yet insufficiently explored question.
